You are here: Home / Journal Articles / Pharmacokinetics, Safety, and Clinical Efficacy of Cannabidiol Treatment in Osteoarthritic Dogs / About

Pharmacokinetics, Safety, and Clinical Efficacy of Cannabidiol Treatment in Osteoarthritic Dogs

By Lauri-Jo Gamble, Jordyn M Boesch, Christopher W Frye, Wayne S Schwark, Sabine Mann, Lisa Wolfe, Holly Brown, Erin S Berthelsen, Joseph J Wakshlag

View Link (HTM)

Licensed under

Category Journal Articles
Abstract

Objectives: The objectives of this study were to determine basic oral pharmacokinetics, and assess safety and analgesic efficacy of a cannabidiol (CBD) based oil in dogs with osteoarthritis (OA).

Methods: Single-dose pharmacokinetics was performed using two different doses of CBD enriched (2 and 8 mg/kg) oil. Thereafter, a randomized placebo-controlled, veterinarian, and owner blinded, cross-over study was conducted. Dogs received each of two treatments: CBD oil (2 mg/kg) or placebo oil every 12 h. Each treatment lasted for 4 weeks with a 2-week washout period. Baseline veterinary assessment and owner questionnaires were completed before initiating each treatment and at weeks 2 and 4. Hematology, serum chemistry and physical examinations were performed at each visit. A mixed model analysis, analyzing the change from enrollment baseline for all other time points was utilized for all variables of interest, with a p ≤ 0.05 defined as significant.

Results: Pharmacokinetics revealed an elimination half-life of 4.2 h at both doses and no observable side effects. Clinically, canine brief pain inventory and Hudson activity scores showed a significant decrease in pain and increase in activity (p < 0.01) with CBD oil. Veterinary assessment showed decreased pain during CBD treatment (p < 0.02). No side effects were reported by owners, however, serum chemistry showed an increase in alkaline phosphatase during CBD treatment (p < 0.01).

Clinical significance: This pharmacokinetic and clinical study suggests that 2 mg/kg of CBD twice daily can help increase comfort and activity in dogs with OA.

Submitter

Marcy Wilhelm-South

Purdue University

Publication Title Frontiers in Veterinary Science
Volume 5
Pages 9
DOI 10.3389/fvets.2018.00165
URL https://www.frontiersin.org/articles/10.3389/fvets.2018.00165/full
Cite this work

Researchers should cite this work as follows:

  • Lauri-Jo Gamble; Jordyn M Boesch; Christopher W Frye; Wayne S Schwark; Sabine Mann; Lisa Wolfe; Holly Brown; Erin S Berthelsen; Joseph J Wakshlag (2018), "Pharmacokinetics, Safety, and Clinical Efficacy of Cannabidiol Treatment in Osteoarthritic Dogs," http://habricentral.org/resources/63815.

    BibTex | EndNote

Tags
  1. Animal roles
  2. cannabidiol
  3. Dogs
  4. hemp
  5. Mammals
  6. open access
  7. pharmacokinetics
Badges
  1. open access